AstraZeneca_NNP Annual_JJ Report_NNP and_CC 94_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD 6_CD SEGMENT_NNP INFORMATION_NNP The_NNP Groups_NNS activities_NNS are_VBP in_IN one_CD business_NN segment_NN ,_, pharmaceuticals_NNS ._.
There_EX are_VBP no_DT other_JJ significant_JJ classes_NNS of_IN business_NN ,_, either_CC singularly_RB or_CC in_IN aggregate_NN ._.
Geographic_JJ areas_NNS The_DT tables_NNS below_IN show_NN information_NN by_IN geographic_JJ area_NN and_CC ,_, for_IN sales_NNS and_CC property_NN ,_, plant_NN and_CC equipment_NN ,_, material_NN countries_NNS ._.
The_DT figures_NNS show_VBP the_DT sales_NNS ,_, operating_VBG profit_NN before_IN tax_NN made_VBN by_IN companies_NNS located_VBN in_IN that_DT area_NN country_NN ,_, together_RB with_IN segment_NN assets_NNS ,_, segment_NN assets_NNS acquired_VBN ,_, net_JJ operating_NN assets_NNS and_CC property_NN ,_, plant_NN and_CC equipment_NN owned_VBN by_IN the_DT same_JJ companies_NNS :_: export_NN sales_NNS and_CC the_DT related_JJ profit_NN are_VBP included_VBN in_IN the_DT area_NN country_NN from_IN which_WDT those_DT sales_NNS were_VBD made_VBN ._.
In_IN the_DT US_NNP ,_, sales_NNS to_TO three_CD wholesalers_NNS accounted_VBD for_IN approximately_RB 80_CD %_NN of_IN US_NNP sales_NNS 2004_CD three_CD wholesalers_NNS for_IN 80_CD %_NN ,_, 2003_CD five_CD wholesalers_NNS for_IN 87_CD %_NN ._.
Intra-Group_NNP pricing_NN is_VBZ determined_VBN on_IN an_DT arms_NNS length_NN basis_NN ._.
Financial_NNP Statements_NNP 95_CD 6_CD SEGMENT_NNP INFORMATION_NNP CONTINUED_VBD Geographic_JJ markets_NNS The_DT table_NN below_IN shows_NNS turnover_NN in_IN each_DT geographic_JJ market_NN in_IN which_WDT customers_NNS are_VBP located_VBN ._.
Net_JJ operating_NN assets_NNS exclude_VBP short_JJ term_NN investments_NNS ,_, cash_NN ,_, short_JJ term_NN borrowings_NNS ,_, loans_NNS and_CC non-operating_JJ receivables_NN and_CC payables_NNS ._.
